相似文献
1
Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8.
Cancer Lett. 2010 May 28;291(2):237-45. doi: 10.1016/j.canlet.2009.10.018. Epub 2009 Nov 30.
2
A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity.
Cancer Lett. 2011 Mar 1;302(1):76-83. doi: 10.1016/j.canlet.2010.12.018. Epub 2011 Jan 12.
3
Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
Oncogene. 2007 Apr 26;26(19):2685-94. doi: 10.1038/sj.onc.1210089. Epub 2006 Oct 30.
4
Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.
Oncogene. 2009 May 21;28(20):2100-11. doi: 10.1038/onc.2009.74. Epub 2009 Apr 20.
5
Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth.
Mol Cancer. 2014 Feb 15;13:29. doi: 10.1186/1476-4598-13-29.
6
Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Oncogene. 2005 Nov 10;24(49):7355-68. doi: 10.1038/sj.onc.1208902.
7
Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
Leuk Lymphoma. 2016 Nov;57(11):2661-71. doi: 10.3109/10428194.2016.1160083. Epub 2016 Mar 22.
8
Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8.
Genes Chromosomes Cancer. 2002 May;34(1):129-35. doi: 10.1002/gcc.10051.
9
The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway.
Oncogene. 2002 Dec 12;21(57):8759-68. doi: 10.1038/sj.onc.1206033.
10
Methods for assessing the in vitro transforming activity of NF-κB transcription factor c-Rel and related proteins.
Methods Mol Biol. 2015;1280:427-46. doi: 10.1007/978-1-4939-2422-6_26.
引用本文的文献
1
A conserved core region of the scaffold NEMO is essential for signal-induced conformational change and liquid-liquid phase separation.
J Biol Chem. 2023 Dec;299(12):105396. doi: 10.1016/j.jbc.2023.105396. Epub 2023 Oct 27.
2
A Conserved Core Region of the Scaffold NEMO is Essential for Signal-induced Conformational Change and Liquid-liquid Phase Separation.
bioRxiv. 2023 May 25:2023.05.25.542299. doi: 10.1101/2023.05.25.542299.
3
Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
Leuk Lymphoma. 2016 Nov;57(11):2661-71. doi: 10.3109/10428194.2016.1160083. Epub 2016 Mar 22.
4
Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
Oncotarget. 2015 Sep 15;6(27):23157-80. doi: 10.18632/oncotarget.4319.
5
The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
J Biol Chem. 2015 Sep 11;290(37):22649-61. doi: 10.1074/jbc.M115.658468. Epub 2015 Jul 30.
6
Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy.
Genes Cancer. 2015 May;6(5-6):184-213. doi: 10.18632/genesandcancer.65.
7
The epigenetic basis of diffuse large B-cell lymphoma.
Semin Hematol. 2015 Apr;52(2):86-96. doi: 10.1053/j.seminhematol.2015.01.003. Epub 2015 Jan 19.
8
The gene expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 in B-Lymphoma cells.
Cancer Biol Med. 2014 Sep;11(3):202-7. doi: 10.7497/j.issn.2095-3941.2014.03.006.
9
Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth.
Mol Cancer. 2014 Feb 15;13:29. doi: 10.1186/1476-4598-13-29.
10
CluGene: A Bioinformatics Framework for the Identification of Co-Localized, Co-Expressed and Co-Regulated Genes Aimed at the Investigation of Transcriptional Regulatory Networks from High-Throughput Expression Data.
PLoS One. 2013 Jun 18;8(6):e66196. doi: 10.1371/journal.pone.0066196. Print 2013.
本文引用的文献
1
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
Nature. 2009 Jun 4;459(7247):717-21. doi: 10.1038/nature07968. Epub 2009 May 3.
2
TRAF6 autoubiquitination-independent activation of the NFkappaB and MAPK pathways in response to IL-1 and RANKL.
PLoS One. 2008;3(12):e4064. doi: 10.1371/journal.pone.0004064. Epub 2008 Dec 29.
3
Ser484 and Ser494 in REL are the major sites of IKK phosphorylation in vitro: evidence that IKK does not directly enhance GAL4-REL transactivation.
Gene Expr. 2008;14(4):195-205. doi: 10.3727/105221608786883807.
4
Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20.
J Mol Biol. 2008 Feb 15;376(2):526-40. doi: 10.1016/j.jmb.2007.11.092. Epub 2007 Dec 4.
5
MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65.
J Immunol. 2007 Nov 15;179(10):7101-9. doi: 10.4049/jimmunol.179.10.7101.
6
Distinct roles of different NF-kappa B subunits in regulating inflammatory and T cell stimulatory gene expression in dendritic cells.
J Immunol. 2007 Jun 1;178(11):6777-88. doi: 10.4049/jimmunol.178.11.6777.
7
Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB.
Mol Cell. 2007 Apr 13;26(1):75-87. doi: 10.1016/j.molcel.2007.02.019.
8
An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
Oncogene. 2007 Jun 7;26(27):4038-43. doi: 10.1038/sj.onc.1210164. Epub 2006 Dec 18.
9
Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
Oncogene. 2007 Apr 26;26(19):2685-94. doi: 10.1038/sj.onc.1210089. Epub 2006 Oct 30.
10
Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Oncogene. 2005 Nov 10;24(49):7355-68. doi: 10.1038/sj.onc.1208902.
Zotero 插件